Accelerating Growth Opportunities

Cathy Doherty

Senior Vice President & Group

Executive – Clinical Franchise Solutions

Dermot Shorten

Senior Vice President – Strategy,

M&A and Ventures

Jay Wohlgemuth, MD

Chief Medical Officer & Senior Vice

President – Research & Development

and Medical

Confidential | Internal Use Only 2

SAFE HARBOR DISCLOSURE

The statements in the following presentation that are not historical facts may be forward-looking

statements. Readers are cautioned not to place undue reliance on forward-looking statements,

which speak only as of the date that they are made and which reflect management’s current

estimates, projections, expectations or beliefs and which involve risks and uncertainties that could

cause actual results and outcomes to be materially different. Risks and uncertainties that may

affect the future results of the Company include, but are not limited to, adverse results from

pending or future government investigations, lawsuits or private actions, the competitive

environment, changes in government regulations, changing relationships with customers, payers,

suppliers or strategic partners and other factors discussed in the Company's most recently filed

Annual Report on Form 10-K and in any of the Company's subsequently filed Quarterly Reports on

Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk

Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and

Analysis of Financial Condition and Results of Operations” sections of those reports.

Confidential | Internal Use Only 3

Advanced diagnostics – delivering high clinical value to the medical community across the U.S.

Hepatitis C

detection and cure

Mosquito borne

infection (Zika)

Non-Invasive

Prenatal Testing

Cancer

genomics

1

3

2

4

Confidential | Internal Use Only 4

We have multiple consumer-centric initiatives focused on securing growth in today’s changing healthcare landscape

Consistent

and Superior

Experience

Retail Consumer

Partnerships

Consumer

Testing Offerings

Information

and Connection

1

3

2

4

Confidential | Internal Use Only 5

IBM Watson Genomics from Quest Diagnostics

Quest Diagnostics: Cancer

precision medicine services /

IBM Watson Genomics form

Quest Diagnostics

IBM Watson: All of the worlds’

data on drugs and cancer

response and cancer clinical

trials

MSKCC: World-leading

expertise on molecular

oncology and precision

medicine

5

Confidential | Internal Use Only 6

Data Diagnostics™, our partnership with Inovalon, delivers real time patient insight in the physician’s workflow – initial customers secured

Solution Challenge Achieving high-quality results despite

disconnected data and complex quality

standards

Data Diagnostics™ provides on-demand, point of care

info within existing workflow to address gaps in care,

provide insights and manage utilization

Confidential | Internal Use Only 8

Quest Diagnostics is accelerating efforts to monetize its data assets

In Market

In Development

DATA INSIGHTS / SOLUTIONS

Post-Market Launch Pharma Data Services

2

Clinical Trial Patient Recruitment

1

Lab Related Analytics

& Services 3

Pre-Market Launch Pharma Data Services

4

Data Diagnostics™ 5

Confidential | Internal Use Only 9

Drug overdose death rates

Opioid pain relievers and heroin drove a new record in drug overdose deaths in 2014 with more than 47,000 overdose deaths.

Overdose Death Rate 1999 Overdose Death Rate 2014

Source: “Drug Poisoning Mortality: United States, 2002–2014”, National Center for Health Statistics, Centers for Disease Control and Prevention

INVESTOR MEETING

2016